The Business Research Company’s report on the Oncology Based In-Vivo CRO Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the oncology based in-vivo cro market in recent years?
The growing prevalence of cancer is expected to propel the growth of the oncology-based in-vivo CRO market going forward. Cancer refers to a group of diseases in which abnormal cells divide uncontrollably, go beyond their usual boundaries, originate in almost any organ or tissue of the body, and spread through the blood and lymph systems to other parts of the body. Treatment and diagnosis of cancer require innovative drugs and devices, which undergo different preclinical trials, clinical trials, and regulatory processes before they enter the market. An oncology in-vivo-based CRO is a company hired by a sponsor company that provides research services such as performing complete or partial steps of running a preclinical in-vivo study (testing or with living organisms such as animals, plants, or whole cells) before the drug or device is trialed in humans. With the increasing prevalence of cancer, the demand for innovative treatments and therapies has also increased, driving the growth of the oncology-based in-vivo CRO market. For instance, in April 2024, the American Cancer Society, a US-based non-profit organization, there were roughly 609,000 cancer-related deaths and 1.9 million new cancer cases identified in the country in 2022. An estimated 620,000 cancer deaths are anticipated, which would represent a little increase in mortality rates in 2024. The growing prevalence of cancer is driving the oncology-based in-vitro CRO market.
Access Your Free Sample of the Global Oncology Based In-Vivo CRO Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp
What is the projected market size of the oncology based in-vivo cro industry, and how is it expected to grow?
The oncology based in-vivo cro market size has grown strongly in recent years. It will grow from$1.39 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increasing focus on oncology therapeutics, increasing incidence of cancer, shift towards personalized medicine, pharmaceutical industry growth, and demand for target-specific therapies
The oncology based in-vivo cro market size is expected to see rapid growth in the next few years. It will grow to “$2.28 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to emerging market opportunities, a shift towards immuno-oncology therapies, a rise in oncology clinical trials, precision medicine, and targeted therapies. Major trends in the forecast period include regenerative medicine and cell therapies, demand for faster drug development, digitalization and data analytics, focus on tumor microenvironment, and rise in biologics and immunotherapies.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp
Who are the key players driving competition in the oncology based in-vivo cro market?
Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.
What key trends are expected to drive the olive oil market during the forecast period?
Major companies operating in the oncology-based in vivo CRO market are focusing on personalized oncology models to gain a competitive advantage. Personalized oncology models utilize patient-derived xenografts (PDXs) to create tailored treatment strategies, enhancing the relevance and efficacy of preclinical studies. For instance, in 2022, Charles River Laboratories, a U.S.-based life sciences company, launched its OncoMouse platform, which incorporates PDX technology for more accurate tumor modeling. This platform features high-throughput screening capabilities and real-time monitoring of tumor growth, allowing for rapid assessment of therapeutic responses. Additionally, it provides integrated data analytics to optimize treatment protocols based on individual patient profiles. These advancements signify a shift towards more effective and patient-centric approaches in cancer research.
Which key geographies are driving the growth of the oncology based in-vivo cro market?
North America was the largest region in the oncology-based in-vivo CRO market in 2024.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology-based in-vivo CRO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report
What are the key segments driving growth in the oncology based in-vivo cro market?
The oncology based in-vivo cro market covered in this report is segmented –
1) By Indication: Blood Cancer, Solid Tumors, Other Indications
2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models
3) By Application: Hospitals, Rehabilitation Centers
Subsegments:
1) By Blood Cancer: Leukemia, Lymphoma, Myeloma
2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Solid Tumors
3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas, Other Specific Indications
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10521
What defines the structure and scope of the oncology based in-vivo cro market?
An oncology-based in-vivo contract research organization (CRO) refers to a company hired by another company to perform complete or partial steps of running a preclinical in-vivo study (testing or with living organisms such as animals, plants, or whole cells), such as designing, managing, monitoring, and analyzing in-vivo preclinical results for oncology drugs or devices.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
